This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (313)

Published on in Vol 9, No 4 (2020): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16664, first published .
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Authors of this article:

Peter A Merkel1, 2 Author Orcid Image ;   David R Jayne3 Author Orcid Image ;   Chao Wang4 Author Orcid Image ;   Jan Hillson5 Author Orcid Image ;   Pirow Bekker5 Author Orcid Image
Article Authors Cited by (51) Tweetations (8) Metrics

Journals

  1. Kitching A, Anders H, Basu N, Brouwer E, Gordon J, Jayne D, Kullman J, Lyons P, Merkel P, Savage C, Specks U, Kain R. ANCA-associated vasculitis. Nature Reviews Disease Primers 2020;6(1) View
  2. Bantis K, Stangou M, Kalpakidis S, Hatziadamou M, Daikidou D, Lioulios G, Mitsoglou Z, Chatzidrosou H, Nikolaidou C, Fylaktou A, Papagianni A. Systemic complement activation in anti‐neutrophil cytoplasmic antibody‐associated vasculitis and necrotizing glomerulonephritis. Nephrology 2021;26(1):30 View
  3. Nasser M, Cottin V. New therapeutic strategies in lung vasculitis. Current Opinion in Pulmonary Medicine 2020;26(5):496 View
  4. Monti S, Quinn K, Christensen R, Jayne D, Langford C, Lanier G, Mahr A, Pagnoux C, Viðarsdóttir M, Merkel P, Tomasson G. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Seminars in Arthritis and Rheumatism 2020;50(6):1314 View
  5. Beketova Т, Nasonov E. Vasculopathy in patients with severe COVID-19 infection. Clinical Medicine (Russian Journal) 2020;98(5):325 View
  6. Antonelou M, Evans R, Henderson S, Salama A. Neutrophils are key mediators in crescentic glomerulonephritis and targets for new therapeutic approaches. Nephrology Dialysis Transplantation 2022;37(2):230 View
  7. Budge K, Dellepiane S, Yu S, Cravedi P. Complement, a Therapeutic Target in Diabetic Kidney Disease. Frontiers in Medicine 2021;7 View
  8. Merkel P, Niles J, Jimenez R, Spiera R, Rovin B, Bomback A, Pagnoux C, Potarca A, Schall T, Bekker P. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. ACR Open Rheumatology 2020;2(11):662 View
  9. Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Frontiers in Immunology 2021;11 View
  10. Keragala C, Woodruff T, Liu Z, Niego B, Ho H, McQuilten Z, Medcalf R. Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement. Frontiers in Neurology 2020;11 View
  11. Specks U, Fussner L, Cartin-Ceba R, Casal Moura M, Zand L, Fervenza F. Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrology Dialysis Transplantation 2021;36(2):231 View
  12. Anliker-Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Frontiers in Immunology 2020;11 View
  13. Poppelaars F, Thurman J. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175 View
  14. Jayne D, Merkel P, Schall T, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine 2021;384(7):599 View
  15. Nozaki Y. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis. Frontiers in Immunology 2021;12 View
  16. Tsukui D, Kimura Y, Kono H. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody（ANCA）-associated vasculitis. Journal of Translational Autoimmunity 2021;4:100094 View
  17. Portilla D, Xavier S. Role of intracellular complement activation in kidney fibrosis. British Journal of Pharmacology 2021;178(14):2880 View
  18. Samman K, Ross C, Pagnoux C, Makhzoum J, Rothschild B. Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives. International Journal of Rheumatology 2021;2021:1 View
  19. Keyßer G. Sicherheitsaspekte der Therapie mit Glukokortikoiden bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 2021;80(4):295 View
  20. Giorgio C, Zippoli M, Cocchiaro P, Castelli V, Varrassi G, Aramini A, Allegretti M, Brandolini L, Cesta M. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives. Biomedicines 2021;9(4):399 View
  21. Pagnoux C, Fifi-Mah A. Update on Maintenance Therapies for ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology 2021;7(2):112 View
  22. Jain K, Jawa P, Derebail V, Falk R. Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis. Kidney360 2021;2(4):763 View
  23. Monti S, Brandolino F, Milanesi A, Xoxi B, Delvino P, Montecucco C. Novel Therapies for ANCA-associated Vasculitis. Current Rheumatology Reports 2021;23(6) View
  24. Falk R. Should PLEX Be Used for Severe AKI and/or Pulmonary Hemorrhage in ANCA-Associated Vasculitis (AAV)? COMMENTARY. Kidney360 2021;2(5):782 View
  25. Floyd L, Morris A, Joshi M, Dhaygude A. Glucocorticoid Therapy in ANCA Vasculitis: Using the Glucocorticoid Toxicity Index as an Outcome Measure. Kidney360 2021;2(6):1002 View
  26. Jalink M, de Boer E, Evers D, Havinga M, Vos J, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Seminars in Immunopathology 2021;43(6):799 View
  27. Benedetto Tiz D, Bagnoli L, Rosati O, Marini F, Sancineto L, Santi C. New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. Molecules 2022;27(5):1643 View
  28. Fenoglio R, Roccatello D, Sciascia S. Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly. Kidney and Blood Pressure Research 2020;45(6):784 View
  29. d’Alessandro M, Conticini E, Bergantini L, Cameli P, Cantarini L, Frediani B, Bargagli E. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review. Life 2022;12(2):317 View
  30. Mandell M, Gheriani G, Lenert A, Lenert P. Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis. Rheumatology 2022;1(1):23 View
  31. Poledniczek M. Coronary Artery Disease in Granulomatosis with Polyangiitis: a Review. SN Comprehensive Clinical Medicine 2022;4(1) View
  32. Patel N, Jayne D, Merkel P, Bekker P, Zhang Y, Yue H, Stone J. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. The Lancet Rheumatology 2023;5(3):e130 View
  33. Suprun M, Beketova T, Babak V, Evsikova M. Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report. Ophthalmology in Russia 2022;19(2):452 View
  34. Nekrasova K, Ischenko A, Trofimov A. Inhibition of the complement anaphylatoxin activities in the central nervous system disorders. Medical academic journal 2021;21(2):37 View
  35. Spera M, Cesta M, Zippoli M, Varrassi G, Allegretti M. Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis. Pain and Therapy 2022;11(4):1113 View
  36. Cortazar F, Niles J, Jayne D, Merkel P, Bruchfeld A, Yue H, Schall T, Bekker P, Peh C, Chakera A, Cooper B, Kurtkoti J, Langguth D, Levidiotis V, Luxton G, Mount P, Mudge D, Noble E, Phoon R, Ranganathan D, Ritchie A, Ryan J, Suranyi M, Rosenkranz A, Lhotta K, Kronbichler A, Demoulin N, Bovy C, Hellemans R, Hougardy J, Sprangers B, Wissing K, Pagnoux C, Barbour S, Brachemi S, Cournoyer S, Girard L, Laurin L, Liang P, Philibert D, Walsh M, Tesar V, Becvar R, Horak P, Rychlik I, Szpirt W, Dieperink H, Gregersen J, Ivarsen P, Krarup E, Lyngsoe C, Rigothier C, Augusto J, Belot A, Chauveau D, Cornec D, Jourde-Chiche N, Ficheux M, Karras A, Klein A, Maurier F, Mesbah R, Moranne O, Neel A, Quemeneur T, Saadoun D, Terrier B, Zaoui P, Schaier M, Benck U, Bergner R, Busch M, Floege J, Grundmann F, Haller H, Haubitz M, Hellmich B, Henes J, Hohenstein B, Hugo C, Iking-Konert C, Arndt F, Kubacki T, Kotter I, Lamprecht P, Lindner T, Halbritter J, Mehling H, Schönermarck U, Venhoff N, Vielhauer V, Witzke O, Szombati I, Szucs G, Garibotto G, Alberici F, Brunetta E, Dagna L, De Vita S, Emmi G, Gabrielli A, Manenti L, Pieruzzi F, Roccatello D, Salvarani C, Dobashi H, Atsumi T, Fujimoto S, Hagino N, Ihata A, Kaname S, Kaneko Y, Katagiri A, Katayama M, Kirino Y, Kitagawa K, Komatsuda A, Kono H, Kurasawa T, Matsumura R, Mimura T, Morinobu A, Murakawa Y, Naniwa T, Nanki T, Ogawa N, Oshima H, Sada K, Sugiyama E, Takeuchi T, Taki H, Tamura N, Tsukamoto T, Yamagata K, Yamamura M, van Daele P, Rutgers A, Teng Y, Walker R, Chua I, Collins M, Rabindranath K, de Zoysa J, Svensson M, Grevbo B, Kalstad S, Little M, Clarkson M, Molloy E, Pamplona I, Anton J, Lucia V, Ciggaran S, Cid M, Encarnacion M, Oliveras X, Soler M, Rusinol H, Praga M, Porras L, Segarra A, Bruchfeld A, Segelmark M, Soveri I, Thomaidi E, Westman K, Neumann T, Burnier M, Daikeler T, Dudler J, Hauser T, Seeger H, Vogt B, Jayne D, Burton J, Al Jayyousi R, Amin T, Andrews J, Baines L, Brogan P, Dasgupta B, Doulton T, Flossmann O, Griffin S, Harper J, Harper L, Kidder D, Klocke R, Lanyon P, Luqmani R, McLaren J, Makanjuola D, McCann L, Nandagudi A, Selvan S, O'Riordan E, Patel M, Patel R, Pusey C, Rajakariar R, Robson J, Robson M, Salama A, Smyth L, Sznajd J, Taylor J, Merkel P, Sreih A, Belilos E, Bomback A, Carlin J, Chen Lin Y, Derebail V, Dragoi S, Dua A, Forbess L, Geetha D, Gipson P, Gohh R, Greenwood G, Hugenberg S, Jimenez R, Kaskas M, Kermani T, Kivitz A, Koening C, Langford C, Marder G, Mohamed A, Monach P, Neyra N, Niemer G, Niles J, Obi R, Owens C, Parks D, Podoll A, Rovin B, Sam R, Shergy W, Silva A, Specks U, Spiera R, Springer J, Striebich C, Swarup A, Thakar S, Tiliakos A, Tsai Y, Waguespack D, Wasko M. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney International Reports 2023;8(4):860 View
  37. Sims C, Golenbiewski J, Eudy A, Allen N, Clowse M. Hospital Admissions and Mortality in Patients With Anti–Neutrophil Cytoplasmic Antibody–Associated Vasculitis. JCR: Journal of Clinical Rheumatology 2023;29(6):e124 View
  38. Stone J, McDowell P, Jayne D, Merkel P, Robson J, Patel N, Zhang Y, Yue H, Bekker P, Heaney L. The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Seminars in Arthritis and Rheumatism 2022;55:152010 View
  39. Levien T, Baker D. Avacopan. Hospital Pharmacy 2023;58(2):134 View
  40. Pette C, Toledanes G, Pereira M. Respiratory Distress and Macular Rash in a 13-year-old Girl. Pediatrics In Review 2023;44(3):165 View
  41. Araújo Correia J, Crespo J, Alves G, Salvador F, Matos-Costa J, Alves J, Fortuna J, Almeida I, Campar A, Brandão M, Faria R, Marado D, Oliveira S, Santos L, Silva F, Vasconcelos C, Fernandes M, Marinho A. Biologic therapy in large and small vessels vasculitis, and Behçet’s disease: Evidence- and practice-based guidance. Autoimmunity Reviews 2023;22(8):103362 View
  42. Fujimoto S. ANCA-associated Vasculitis: Focusing on Recent Advances in Medical Care. The Journal of Japanese College of Angiology 2023;63(5):75 View
  43. Patel N, Jayne D, Merkel P, Bekker P, Zhang Y, McDowell P, Johal J, Heaney L, Murrell D, Stone M, Yue H, Stone J. The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial. The Lancet Rheumatology 2023;5(7):e413 View
  44. Kareem S, Jacob A, Mathew J, Quigg R, Alexander J. Complement: Functions, location and implications. Immunology 2023;170(2):180 View
  45. Gomez‐Arboledas A, Fonseca M, Kramar E, Chu S, Schartz N, Selvan P, Wood M, Tenner A. C5aR1 signaling promotes region‐ and age‐dependent synaptic pruning in models of Alzheimer's disease. Alzheimer's & Dementia 2024;20(3):2173 View
  46. Bunch D, Lewis S, Xiao H, Hu P, Jennette J, Wu E. Complement as a major mediator of ANCA vasculitis and a target for precision therapy. Expert Review of Clinical Immunology 2024:1 View
  47. Tesar V, Hartinger J, Hruskova Z. Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview. Expert Review of Clinical Pharmacology 2024:1 View

Books/Policy Documents

  1. Jacotot E, Talamini L, Bonam S, Vieira A, Fremeaux-Bacchi V, Radic M, Dragon-Durey M, Lozano J, Saia R, Muller S. Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination. View
  2. Araujo E, Bell I, Burckle A, Koester D, Manning J, Caldwell R, Castanedo G, Green S, Zeng M, Debien L, Dhar T, Holmberg-Douglas N, Welin E, Merritt J, Peese K, Grünenfelder D, Lo J. 2022 Medicinal Chemistry Reviews. View
  3. Twardy S, Frazer-Abel A, McCullough R. Reference Module in Biomedical Sciences. View
  4. Dixon B, Purohit S, Frazer‐Abel A. Manual of Molecular and Clinical Laboratory Immunology. View